BCABNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Market cap
$5.742 M
$3.46 +3.90%
Close of 7 Aug 2026
Revenue
—
Not reported
Earnings
$59.6M
#1505 by earnings
Shares outstanding
1,659,612
Latest filing cover page
P/E ratio
0.1
Cap ÷ net income
Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap
All 160 →Where these numbers come from
Share counts and financials for BioAtla are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.